BioCentury
ARTICLE | Financial News

Zealand lists on NASDAQ

August 9, 2017 8:25 PM UTC

Metabolic company Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) began trading on NASDAQ Wednesday after pricing a follow-on of ADSs underwritten by Morgan Stanley and Goldman Sachs. The company raised $78.2 million through the sale of 4.4 million ADSs at $17.87.

Partner Sanofi (Euronext:SAN; NYSE:SNY) markets Zealand's lixisenatide in the U.S. as Adlyxin and in the EU as Lyxumia to treat Type II diabetes. Sanofi also markets a combination of lixisenatide plus its own Lantus insulin glargine in the U.S. as Soliqua 100/33 and in the EU as Suliqua...

BCIQ Company Profiles

Sanofi

Zealand Pharma A/S